Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 12:22 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2425–2448 of 13,632 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Dermatologic Disorders Clear all

Conditions: Breast Cancer, Breast Cancer Non-invasive Breast Cancer, Breast Cancer Early Stage Breast Cancer (Stage 1-3)
Interventions: breast tissue, lymph node tissue or blood; Procedure
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 788 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1996 – 2011
U.S. locations: 1
States / cities: Stanford, California

Conditions: Breast Cancer, Fatigue
Interventions: infliximab, Clinical Assessment, Self-report questionnaires, Immune Assessment; Biological · Other
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: 45 Years to 65 Years · Female only
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2012
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Breast Cancer
Interventions: Screening digital mammography, Screening digital breast tomosynthesis, Screening breast magnetic resonance imaging, Diagnostic mammography, Pre-operative breast magnetic resonance imaging; Other
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years to 89 Years · Female only
Enrollment: 1,341,172 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 7
States / cities: Davis, California • San Francisco, California • Chicago, Illinois + 4 more

Conditions: Breast Cancer, HER-2 Positive Breast Cancer, Triple Negative Breast Cancer, ER/Progressive Response (PR) + Refractory to Prior Hormonal Treatment
Interventions: ganetespib; Drug
Lead sponsor: Synta Pharmaceuticals Corp.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 8
States / cities: Birmingham, Alabama • Altanta, Georgia • Boston, Massachusetts + 5 more

Conditions: Atopic Dermatitis, Eczema
Interventions: Dilute vinegar (acetic acid), Dilute bleach; Other
Lead sponsor: University of Arizona; Other
Eligibility: 5 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: TNBC - Triple-Negative Breast Cancer, Ovarian Cancer
Interventions: Etrumadenant, IPI-549, Pegylated liposomal doxorubicin (PLD), nanoparticle albumin-bound paclitaxel (NP); Drug
Lead sponsor: Arcus Biosciences, Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 20
States / cities: Scottsdale, Arizona • Tucson, Arizona • Los Angeles, California + 16 more

Conditions: Triple-Negative Breast Cancer
Interventions: Atezolizumab, Ipatasertib, Paclitaxel, Placebo for Atezolizumab, Placebo for Ipatasertib; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 242 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 31
States / cities: Mobile, Alabama • Springdale, Arkansas • Los Angeles, California + 25 more

Conditions: HER2-Positive Breast Carcinoma, Invasive Breast Carcinoma, Metastatic Malignant Neoplasm in the Brain, Recurrent Breast Carcinoma, Stage IV Breast Cancer AJCC v6 and v7
Interventions: Laboratory Biomarker Analysis, Lapatinib Ditosylate, Stereotactic Radiosurgery, Whole-Brain Radiotherapy; Other · Drug · Radiation
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 143 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2022
U.S. locations: 292
States / cities: Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 210 more

Conditions: Systemic Sclerosis
Interventions: Placebo matching nerandomilast formulation 1, Placebo matching nerandomilast formulation 2, Nerandomilast formulation 1, Nerandomilast formulation 2; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 448 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 30
States / cities: Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 23 more

Conditions: Infertility
Interventions: Tamoxifen, Letrozole; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 309 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2028
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Idiopathic Inflammatory Myopathy, Dermatomyositis, Anti-Synthetase Syndrome, Immune-Mediated Necrotizing Myopathy, Juvenile Dermatomyositis, Juvenile Polymyositis, Juvenile Idiopathic Inflammatory Myopathy (JIIM), Juvenile Myositis
Interventions: CABA-201 following preconditioning with fludarabine and cyclophosphamide; Biological
Lead sponsor: Cabaletta Bio; Industry
Eligibility: 6 Years to 75 Years
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 31
States / cities: Orange, California • San Francisco, California • Aurora, Colorado + 22 more

Conditions: X-linked Hypohidrotic Ectodermal Dysplasia
Interventions: EDI200; Drug
Lead sponsor: Edimer Pharmaceuticals; Industry
Eligibility: 18 Years to 40 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 2
States / cities: San Francisco, California • Cincinnati, Ohio

Conditions: Psoriatic Arthritis
Interventions: Alefacept, Methotrexate, Placebo; Drug
Lead sponsor: Astellas Pharma Inc; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 185 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2005
U.S. locations: 5
States / cities: Birmingham, Alabama • Wheaton, Maryland • Lake Success, New York + 2 more

Conditions: ER-Positive HER2-Negative Breast Cancer
Interventions: Camizestrant, Ribociclib; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 12
States / cities: Duarte, California • Palo Alto, California • Marietta, Georgia + 9 more

Conditions: Locally Advanced Breast Cancer, Unresectable Breast Carcinoma, Metastatic Breast Cancer
Interventions: BNT323, BNT327; Drug
Lead sponsor: BioNTech SE; Industry
Eligibility: 18 Years and older
Enrollment: 380 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 29
States / cities: Beverly Hills, California • Newport Beach, California • Port Saint Lucie, Florida + 19 more

Conditions: Atopic Dermatitis
Interventions: FB825, Placebo; Drug
Lead sponsor: Oneness Biotech Co., Ltd.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 114 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 6
States / cities: Fountain Valley, California • Fremont, California • Los Angeles, California + 3 more

Conditions: Acne Vulgaris
Interventions: SB204 4%, Vehicle Gel; Drug
Lead sponsor: Novan, Inc.; Industry
Eligibility: 9 Years to 99 Years
Enrollment: 1,330 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016
U.S. locations: 55
States / cities: Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 50 more

Conditions: Vitiligo
Interventions: ruxolitinib, Vehicle; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 12 Years and older
Enrollment: 458 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 44
States / cities: Hoover, Alabama • Gilbert, Arizona • Fountain Valley, California + 36 more

Conditions: Breast Cancer, Malignant Neoplasm of Breast
Interventions: Palbociclib, Aromatase inhibitor, Ribociclib, Abemaciclib; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: New York, New York

Conditions: Psoriasis
Interventions: Guselkumab, Placebo, Secukinumab; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 1,048 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 44
States / cities: Birmingham, Alabama • Los Angeles, California • Oceanside, California + 38 more

Conditions: Skin Cancer
Interventions: Health Chat including Indoor Tanning, Health Chat excluding Indoor Tanning; Behavioral
Lead sponsor: Klein Buendel, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 1,607 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2022
U.S. locations: 4
States / cities: Fort Collins, Colorado • Golden, Colorado • Storrs, Connecticut + 1 more

Conditions: Metastatic Malignant Melanoma
Interventions: Temozolomide and SU11248; Drug
Lead sponsor: Northern California Melanoma Center; Other
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Squamous Cell Carcinoma of Skin, Carcinoma, Squamous Cell
Interventions: Pegylated Interferon alpha-2b, Capecitabine, 5-FU; Drug
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Breast Neoplasms
Interventions: Mammography and tomosynthesis imaging; Radiation
Lead sponsor: Duke University; Other
Eligibility: Female only
Enrollment: 385 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2013
U.S. locations: 1
States / cities: Durham, North Carolina

Search by objective public record fields.

Molecular Analysis of Breast Cancer

Infliximab in Treating Cancer-Related Fatigue in Postmenopausal Women Who Have Undergone Treatment for Breast Cancer

Assessing Breast Density's Value in Imaging - A Comparative Effectiveness Study

An Open-Label Multicenter Phase 2 Window of Opportunity Study Evaluating Ganetespib in Women With Breast Cancer

Evaluating the Effect of Bathing Additives in Atopic Dermatitis

A Study to Evaluate Safety/Tolerability of Immunotherapy Combinations in Participants With Triple-Negative Breast Cancer or Gynecologic Malignancies

A Study of Ipatasertib in Combination With Atezolizumab and Paclitaxel as a Treatment for Participants With Locally Advanced or Metastatic Triple-Negative Breast Cancer

Whole-Brain Radiation Therapy or Stereotactic Radiosurgery With or Without Lapatinib Ditosylate in Treating Patients With Brain Metastasis From HER2-Positive Breast Cancer

A Study to Test Whether Nerandomilast Helps People With Systemic Sclerosis

Fertility Preservation Using Tamoxifen and Letrozole in Estrogen Sensitive Tumors Trial

RESET-Myositis: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy

A Phase 1, Open-label, Multicenter, Safety and Pharmacokinetic Study of EDI200

A Placebo-controlled Study With an Extension Examining the Safety and Efficacy of Alefacept in Psoriatic Arthritis

A Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast Cancer

A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer

Evaluate Efficacy and Safety of Repeat Subcutaneous Doses of FB825 in Adults With Moderate-to-Severe Atopic Dermatitis

P3 Study Comparing Once Daily SB204 and Vehicle Gel in Acne

Assess the Long Term Efficacy and Safety of Ruxolitinib Cream in Participants With Vitiligo

A Real-life Study to Understand the Use and Effects of Palbociclib in US Patients With Breast Cancer

A Study to Evaluate the Comparative Efficacy of CNTO 1959 (Guselkumab) and Secukinumab for the Treatment of Moderate to Severe Plaque-type Psoriasis

Engaging Moms on Teen Indoor Tanning Through Social Media

Temodar and Sutent as Therapy for Melanoma

Capecitabine or 5-FU With Pegylated Interferon Alpha-2b in Unresectable/Metastatic Cutaneous Squamous Cell Carcinoma

Early Detection of Breast Cancer Using Tomosynthesis Imaging